Skip to content
PICO Portalanswers from OpenAlex

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

PaperCitations, authors & open-access status

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is a paper indexed in PICO Portal from OpenAlex.

How many citations does Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study have?

PICO Portalcitation count

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has 338 citations in the OpenAlex counts PICO Portal stores.

When was Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study published?

PICO Portalyear

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has 2021 year in the PICO Portal index.

What is the open-access status of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?

PICO Portaloa status

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study has bronze oa status in the PICO Portal index.

What is the DOI of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?

PICO Portaldoi

The DOI for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.

What is the PMID of Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?

PICO Portalpmid

The PMID for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.

What is the OpenAlex record for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study?

PICO Portalopenalex

The OpenAlex for Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial